Navigation Links
Michael DeMane Joins Thomas, McNerney & Partners as Senior Advisor
Date:4/3/2009

Former Medtronic Chief Operating Officer joins Minneapolis office.

MINNEAPOLIS, April 3 /PRNewswire/ -- Thomas, McNerney & Partners, LLC, a health care venture capital firm that invests in life science and medical technology companies, today announced that Michael DeMane has joined as Senior Advisor in the firm's Minneapolis office. From 2000 to 2008, Mr. DeMane held various senior positions at Medtronic Inc.'s (NYSE: MDT) U.S. and global operations, most recently as its Chief Operating Officer.

"Michael is a proven leader in the medical device industry with an unbroken record of global operating success," said Pete McNerney, Partner. "His extensive knowledge and industry contacts will be a valuable addition to our investment team, both in working with our existing portfolio and in reviewing potential new investments."

Mr. DeMane has more than 25 years of global medical device experience. Prior to his role as Chief Operating Officer at Medtronic, he served as Senior Vice President and President, Europe, Canada, Latin America and Emerging Markets. Previously he was Senior Vice President and President, Spinal, ENT and Navigation, Medtronic's fastest growing business sector, where he was responsible for growing the acquired businesses of Sofamor Danek, Xomed and Surgical Navigation Technologies. Prior to joining Medtronic, Mr. DeMane was President, Interbody Technologies, a division of Sofamor Danek and he held various senior positions at Smith & Nephew, Inc. including Managing Director for operations in Australia and New Zealand and President of the Orthopedic Implant Division. "Thomas, McNerney & Partners has extensive investment experience and wide contacts in the medical technology industry," said Mr. DeMane. "I look forward to assisting them with their portfolio companies and investment process."

About Thomas, McNerney & Partners

Thomas, McNerney & Partners is a health care venture capital firm with approximately $600 million under management focused on investing in life science and medical technology companies at all stages of development. In addition to helping entrepreneurs launch companies with seed and early stage funding, the firm provides growth capital to emerging companies to advance clinical development or for product commercialization. Thomas, McNerney & Partners also is involved in spinning out products and divisions from major medical device and pharmaceutical companies, consolidating companies through roll-up strategies and participating in structured financings for public companies as well as recapitalizations. The firm is targeting investments in the pharmaceutical, medical device, biotechnology and diagnostic sectors and in other areas utilizing medical technology innovation. The firm has offices in Minneapolis, Stamford and San Francisco. For further information, please visit www.tm-partners.com.


'/>"/>
SOURCE Thomas, McNerney & Partners, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
2. HealthWorldWeb Adds Michael Millenson and J.D. Kleinke to Board of Advisors
3. Fish health claims may cause more environmental harm than good: UBC-St. Michaels researchers
4. Michael J. Fox Foundation Joins Effort to Recruit 10,000 People With Parkinsons Disease to New Web-Based PD Research Community
5. Rehab Specialist, Michael Fisher, Joins Fast - Growing Alliance Seating & Mobility in North Carolina
6. NewCardio Elects Michael E. Hanson to Board of Directors
7. Michael Forte Joins CONNEXION Healthcare as Chief Operations Officer
8. My1Stop.com President Michael Del Chiaro Interviewed by Entrepreneur.com for ecommerce Expertise
9. ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinsons Disease Research to Develop Tools for Imaging Alpha-Synuclein Aggregation in Living Parkinsons Brain
10. Michael L. Parks, MD, Elected to the American Academy of Orthopaedic Surgeons Board of Directors
11. American TeleCare, Inc. (ATI) Appoints Michael A. Brodeur as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: